FLT3 and myelodysplastic syndrome: Future directions in this scenario will include the validation of the most recent classification, ELN2022: (i) confirmation of the prognostic integration of bZIP CEBPA mutations; (ii) the long-term follow-up of patients treated with FLT3 inhibitors which could overcome prognostic value; (iii) confirmation of adverse outcomes in patients with MDS-related genes mutations; and finally, the possible definition of very-adverse subgroup.